XTL BiopharmaceuticalsXTLB
13F holders, Q3 2025 (September 30)4holders
0new positions
0sold out
$1.17avg. 13F price*
At the end of Q3 2025, 4 institutions reported holding XTL Biopharmaceuticals Ltd. (XTLB) in their 13F filings, unchanged from Q2 2025. 0 opened new positions and 0 sold out. The largest holders were Noked Israel Ltd ($233K), Rhumbline Advisers ($20K) and Morgan Stanley ($12K).
- Company
- XTL Biopharmaceuticals Ltd.
- CUSIP
- 98386D307
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 1,573 shares sold, net −1,573 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Noked Israel Ltd | 0.04% | No change | 198,888 | $233K |
| Rhumbline Advisers | 0.00% | No change | 17,261 | $20K |
| Morgan Stanley | 0.00% | Reduce -9.1% | 10,011 | $12K |
| UBS Group AG | 0.00% | Reduce -42.9% | 763 | $893 |
"% of holder's portfolio" is XTLB's weight in each manager's 13F, not the share of XTL Biopharmaceuticals Ltd. the manager owns.